The UK drug regulator approved AstraZeneca, which is based on COVID-19 antibodies, and is used to prevent infection in people with a weak immune response. Evusheld contains antibodies made in a laboratory that are designed to persist in the body for months to stop the virus in the event of an infection.
The approval decision for Evusheld was approved by the government's independent scientific advisory body. And although 85 percent. In British people over 12 years of age who have been vaccinated with two doses, some people with immunosuppression or a history of serious adverse react...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
